stoxline Quote Chart Rank Option Currency Glossary
  
Prime Medicine, Inc. (PRME)
2.84  0.245 (9.44%)    02-14 16:00
Open: 2.66
High: 2.9
Volume: 1,241,365
  
Pre. Close: 2.595
Low: 2.66
Market Cap: 372(M)
Technical analysis
2025-02-14 4:50:42 PM
Short term     
Mid term     
Targets 6-month :  3.9 1-year :  4.55
Resists First :  3.33 Second :  3.9
Pivot price 2.61
Supports First :  2.66 Second :  2.25
MAs MA(5) :  2.53 MA(20) :  2.74
MA(100) :  3.3 MA(250) :  4.84
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  44.7 D(3) :  25.6
RSI RSI(14): 53.1
52-week High :  9.77 Low :  2.25
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PRME ] has closed below upper band by 16.4%. Bollinger Bands are 26.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.9 - 2.92 2.92 - 2.93
Low: 2.63 - 2.64 2.64 - 2.66
Close: 2.82 - 2.84 2.84 - 2.86
Company Description

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 14 Feb 2025
Prime Medicine, Inc. (NYSE:PRME) Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat

Wed, 05 Feb 2025
Prime Medicine: Gene Editing Company, Risky Investment (NASDAQ:PRME) - Seeking Alpha

Sun, 02 Feb 2025
Analysts Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $13.13 - MarketBeat

Thu, 30 Jan 2025
Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm - PR Newswire

Tue, 07 Jan 2025
Prime Medicine CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Tue, 31 Dec 2024
Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 131 (M)
Held by Insiders 6.042e+007 (%)
Held by Institutions 23.9 (%)
Shares Short 16,130 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.0713e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -25 %
Return on Assets (ttm) 948.3 %
Return on Equity (ttm) -46.6 %
Qtrly Rev. Growth 800000 %
Gross Profit (p.s.) 0
Sales Per Share -54.72
EBITDA (p.s.) -7.74354e+007
Qtrly Earnings Growth -2.1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -183 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.06
Price to Cash Flow 3.98
Stock Dividends
Dividend 0
Forward Dividend 1.721e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android